4QK.F · Codexis, Inc

-

Please sign in to comment on 4QK.F

1 Comment

Admin

4 years, 1 month ago

Codexis, Inc is currently in a long term uptrend where the price is trading 6.9% above its 200 day moving average.

From a valuation standpoint, the stock is 98.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 20.6.

Codexis, Inc's total revenue rose by 12.8% to $21M since the same quarter in the previous year.

Its net income has dropped by 517.3% to $-4M since the same quarter in the previous year.

Finally, its free cash flow grew by 26.9% to $-3M since the same quarter in the previous year.

Based on the above factors, Codexis, Inc gets an overall score of 4/5.

Exchange	F
CurrencyCode	EUR
ISIN	US1920051067
Sector	Healthcare
Industry	Biotechnology

Market Cap	185M
PE Ratio	None
Target Price	29.5
Beta	2.35
Dividend Yield	None

ABOUT

Codexis, Inc

Codexis, Inc. provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, and enhance novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.

4QK.F · Codexis, Inc

-

Codexis, Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Codexis, Inc using a moving average strategy